Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 6254 |
| PDBID: | 8GHR |
| Chains: | D_B |
| Organism: | Homo sapiens |
| Method: | EM |
| Resolution (Å): | 3.20 |
| Reference: | 10.1038/s41589-023-01368-5 |
| Antibody | |
| Antibody: | VH27 VHH |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Human ectodomain phosphatase/phosphodiesterase-1 (ENPP1) |
| Antigen mutation: | No |
| Durg Target: | P22413; P01857; Q6PYX1; P01861; P01860; P01859; |
Sequence information
Antibody
Chain: D
Mutation: NULL
| >8GHR_D|Chain C, D|VH27|Homo sapiens (9606) EVQLVESGGGLVQPGGSLRLSCAASGFDIYYSYYIGWVRRAPGKGEELVARISPSYGSTSYADSVKGRFTISADISKNTAYLQMNSLRVEDTAVYYCARFAYPWYVADDALDYWGQGTLVTVSS |
Antigen
Chain: B
Mutation: NULL
| >8GHR_B|Chain A, B|Ectonucleotide pyrophosphatase/phosphodiesterase family member 1, secreted form, Immunoglobulin gamma-1 heavy chain fusion|Homo sapiens (9606) GEKSWVEEPCESINEPQCPAGFETPPTLLFSLDGFRAEYLHTWGGLLPVISKLKKCGTYTKNMRPVYPTKAFPNHYSIVTGLYPESHGIIDNKMYDPKMNASFSLKSKEKFNPEWYKGEPIWVTAKYQGLKSGTFFWPGSDVEINGIFPDIYKMYNGSVPFEERILAVLQWLQLPKDERPHFYTLYLEEPDSSGHSYGPVSSEVIKALQRVDGMVGMLMDGLKELNLHRCLNLILISDHGMEQGSCKKYIYLNKYLGDVKNIKVIYGPAARLRPSDVPDKYYSFNYEGIARNLSCREPNQHFKPYLKHFLPKRLHFAKSDRIEPLTFYLDPQWQLALNPSERKYCGSGFHGSDNVFSNMQALFVGYGPGFKHGIEADTFENIEVYNLMCDLLNLTPAPNNGTHGSLNHLLKNPVYTPKHPKEVHPLVQCPFTRNPRDNLGCSCNPSILPIEDFQTQFNLTVAEEKIIKHETLPYGRPRVLQKENTICLLSQHQFMSGYSQDILMPLWTSYTVDRNDSFSTEDFSNCLYQDFRIPLSPVHKCSFYKNNTKVSYGFLSPPQLNKNSSGIYSEALLTTNIVPMYQSFQVIWRYFHDTLLRKYAEERNGVNVVSGPVFDFDYDGRCDSLENLRQKRRVIRNQEILIPTHFFIVLTSCKDTSQTPLHCENLDTLAFILPHRTDNSESCVHGKHDSSWVEELLMLHRARITDVEHITGLSFYQQRKEPVSDILKLKTHLPTFSQEDTSSGGGGENLYFQSSGGGSGGGEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGLNDIFEAQKIEWHEG |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| D: VAL2 SER25 GLY26 PHE27 ASP28 TYR30 TYR31 TYR33 SER55 TYR56 ILE75 SER76 LYS77 ASN78 ARG99 TYR102 PRO103 TRP104 TYR105 VAL106 ASP108 TYR113 B: LYS278 LEU290 LYS291 TYR340 GLY342 SER343 VAL344 PRO345 PHE346 GLU347 ARG349 GLU373 GLU374 ASP376 SER377 HIS380 SER381 TYR382 GLU388 ARG395 VAL396 MET399 PRO524 SER525 ARG527 LYS528 TYR529 SER532 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
